Therapeutic leukapheresis in a tertiary care hospital: A case series.
Patients presenting with hyperleukocytosis secondary to acute leukemia, with total leukocyte count or blast count more than 100,000/μL are often considered for leukapheresis, especially if clinical signs of leukostasis are present. Leukostasis is often associated with high morbidity and mortality in patients with leukemic processes. The main goal of management of hyperleukocytosis and/or leukostasis is to reduce the blast count before initiation of chemotherapy. Leukapheresis is often used prophylactically to prevent leukostasis or to provide symptomatic relief. We, as transfusion medicine specialists, present our experience of doing therapeutic leukapheresis in patients presenting with hyperleukocytosis with or without presenting features of leukostasis.
Department of Transfusion Medicine, Indraprastha Apollo Hospital, New Delhi, India.
Raj Nath
RN
Makroo
Department of Transfusion Medicine, Indraprastha Apollo Hospital, New Delhi, India.
Brinda
B
Kakkar
Department of Transfusion Medicine, Indraprastha Apollo Hospital, New Delhi, India.
Mohit
M
Chowdhry
Department of Transfusion Medicine, Indraprastha Apollo Hospital, New Delhi, India.
Soma
S
Agrawal
Department of Hemato-Oncology and Bone Marrow Transplant, Indraprastha Apollo Hospital, New Delhi, India.
Shishir
S
Seth
Department of Transfusion Medicine, Indraprastha Apollo Hospital, New Delhi, India.
Uday K
UK
Thakur
Hyperleukocytosis; leukapheresis; leukoreduction; leukostasis; total leukocyte count